Disability-related costs from multiple sclerosis (MS) place a substantial financial burden on U.S. employers, with annual estimates exceeding $1.1 billion. In a study commissioned by Sanofi, Milliman used actuarial models and commercial claims data to simulate various scenarios of slowing disease progression in the commercially insured MS population to estimate the potential reduction in disability costs for employers.

This paper discusses:

• MS often affects working-age adults, resulting in significant disability-related costs and treatment challenges for employers.
• The recent shift in MS management from focusing on relapse control to slowing disease progression.
• Estimates of disability-related claim costs reductions resulting from scenarios of slower disability progression, based on actuarial models.

This report was commissioned by Sanofi.